Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets

Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the gastroenteropancreatic (GEP) system currently encompasses approved therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib. However, clinical efficacy of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Aristizabal Prada, E T, Auernhammer, C J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754510/
https://www.ncbi.nlm.nih.gov/pubmed/29146887
http://dx.doi.org/10.1530/EC-17-0286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754510/
https://www.ncbi.nlm.nih.gov/pubmed/29146887
http://dx.doi.org/10.1530/EC-17-0286

Ejemplares similares